Type 2 diabetes and risk of colorectal cancer in two large u. S. Prospective cohorts

ABSTRACT BACKGROUND Previous studies have shown a positive association between type 2 diabetes (T2D) and colorectal cancer (CRC) risk. However, it is uncertain whether this association

differs by duration of T2D or sex. We thus investigated the associations of T2D and its duration with the risk of incident CRC. METHODS We followed 87,523 women from the Nurses’ Health Study

(1980–2012) and 47,240 men from the Health Professionals Follow-up Study (1986–2012). Data on physician-diagnosed T2D was collected at baseline with a questionnaire and updated biennially.

Cox regression models were used to estimate multivariable-adjusted hazard ratios (HRs) and 95% confidence intervals (CIs). RESULTS We documented 3000 CRC cases during up to 32 years of

follow-up. Among men, T2D was associated with increased risk of CRC compared to those without T2D (HR: 1.42; 95% CI: 1.12–1.81). This positive association persisted in sensitivity analyses

by excluding CRC identified within 1 year of diabetes diagnosis and patients with T2D who used hypoglycaemic medications. Among women, T2D was positively, but not statistically

significantly, associated with CRC risk (HR: 1.17; 95% CI: 0.98–1.39). CONCLUSIONS Our findings support that T2D was associated with a moderately higher risk of developing CRC in men; a

weaker, nonsignificant positive association was observed in women. SIMILAR CONTENT BEING VIEWED BY OTHERS ASSOCIATIONS OF DIABETES AND MORTALITY AMONG COLORECTAL CANCER PATIENTS FROM THE

SOUTHERN COMMUNITY COHORT STUDY Article 19 July 2024 PREVALENT DIABETES AND RISK OF TOTAL, COLORECTAL, PROSTATE AND BREAST CANCERS IN AN AGEING POPULATION: META-ANALYSIS OF INDIVIDUAL

PARTICIPANT DATA FROM COHORTS OF THE CHANCES CONSORTIUM Article 26 March 2021 BODY MASS INDEX AND CANCER RISK IN PATIENTS WITH TYPE 2 DIABETES: A DOSE–RESPONSE META-ANALYSIS OF COHORT

STUDIES Article Open access 28 January 2021 INTRODUCTION Colorectal cancer is the third most commonly diagnosed cancer in the US1 and worldwide.2 A number of epidemiological studies have

shown that individuals with type 2 diabetes have a higher risk of developing colorectal cancer compared with their non-diabetic

counterparts.3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22 Elevated insulin due to insulin resistance and hyperinsulinaemia, which occurs in the early stages of type 2 diabetes,23 has

been hypothesised to partially explain the proposed type 2 diabetes–colorectal cancer association.24 Insulin is an important growth factor of colonic epithelial cells and is a mitogen of

tumour cell growth in vitro.24 Insulin may also promote colorectal carcinogenesis indirectly through increasing bioavailable insulin-like growth factor 1, which could enhance cell

proliferation and inhibit apoptosis.24 Another potential biological link between type 2 diabetes and cancer is hyperglycaemia, which may impair the effect of ascorbic acid on intracellular

metabolism, reduce the effectiveness of the immune system, and regulate the level of reactive oxygen species, which could favour cancer development and progression in diabetic patients.25

Several issues regarding the association between type 2 diabetes and colorectal cancer risk remained unresolved. First, the relationship between duration of diabetes and colorectal cancer

risk remains uncertain. Some studies have reported a higher risk of colorectal cancer with prolonged duration of type 2 diabetes3,5,26 or with short duration,13 whereas other studies have

shown no difference in risk by duration of type 2 diabetes.7,12 Second, most previous studies only examined a single measurement of diabetes at baseline,4,6,8,10,14,15 which cannot account

for new diagnoses of diabetes during follow-up. Last, published data has shown inconclusive results about the association of type 2 diabetes with the risk of different subsites of colorectal

cancer.27,28,29 The potential gender difference in the type 2 diabetes and colorectal cancer association also remains unclear. This issue is of interest because sex hormones (e.g.

testosterone, oestrogen and progesterone) may play a role in colorectal cancer.30,31,32,33,34,35 To address these issues, we examined whether physician-diagnosed type 2 diabetes and its

duration are associated with the risk of colorectal cancer in the Nurses’ Health Study and the Health Professionals Follow-up Study. In addition, we also examined potential differences in

the association by sex. METHODS STUDY POPULATION We conducted this study by using data from the two large-scale prospective cohort studies: the Nurses’ Health Study and the Health

Professionals Follow-up Study. In brief, the Nurses’ Health Study was initiated in 1976 and included a total of 121,700 US female registered nurses aged 30–55 years. The Health Professionals

Follow-up Study was established in 1986 and included 51,529 male health professionals aged 40–75 years. Participants were followed up biennially by validated questionnaires on demographics,

medical conditions, and health-related behaviours. The validity of questionnaire has been described in detail previously.36 The follow-up rates have been >90% in each cohort. For the

current study, we used 1980 as the baseline for the Nurses’ Health Study and 1986 for the Health Professionals Follow-up Study. We excluded participants with missing data on diabetes, with

unconfirmed diabetes, and with a history of cancer (except for non-melanoma skin cancer) or inflammatory bowel disease at baseline. After exclusions, the final study population consisted of

87,523 women from the Nurses’ Health Study and 47,240 men from the Health Professionals Follow-up Study. The study protocol was approved by the institutional review board of the Brigham and

Women’s Hospital and the Human Subjects Committee Review Board of the Harvard T. H. Chan School of Public Health. ASSESSMENT OF TYPE 2 DIABETES In the baseline and all biennial

questionnaires, the participants were asked if and when they had ever been diagnosed with type 2 diabetes by a physician. To confirm the self-reported cases of physician-diagnosed diabetes,

a supplementary questionnaire was then sent for ascertainment to obtain details about the date of diagnosis, symptoms, diagnostic tests, and hypoglycaemic treatment. Beginning in 1986 in

each cohort, supplementary questionnaires were administered to collect information on antidiabetic drug use (insulin or hypoglycaemic agent) as described in detail previously.37 Cases of

type 2 diabetes were defined as initially self-reported diabetes and subsequently confirmed by the validated questionnaires.38,39 Consistent with previous studies from the same cohorts,40

confirmed diabetes requires at least one of the following criteria reported on the supplementary questionnaire according to the American Diabetes Association: one or more classic symptoms

(excessive thirst, polyuria or frequent urination, weight loss, hunger) plus fasting plasma glucose ≥7.0 mmol/l or random plasma glucose levels ≥11.1 mmol/l; ≥2 elevated plasma glucose

concentrations on different occasions (fasting glucose ≥7.0 mmol/l, random plasma glucose ≥11.1 mmol/l, and/or plasma glucose ≥11.1 mmol/l after ≥2 h shown by oral glucose tolerance testing)

in the absence of symptoms; or treatment with hypoglycaemic medication. Before 1998, fasting plasma glucose of 7.8 mmol/l was considered for the diagnosis of diabetes according to the

National Diabetes Data Group criteria. The validity of the supplementary questionnaire has been confirmed through medical records. In each cohort, diagnosis of type 2 diabetes was confirmed

in >97% of the cases.39,41 ASSESSMENT OF COVARIATES Information on body weight, physical activity, other lifestyle information, and medical history was obtained at baseline and was

updated through biennial questionnaires. Height was ascertained in 1980 in the Nurses’ Health Study and in 1986 in the Health Professionals Follow-up Study. We calculated body mass index

(BMI) as weight in kilograms divided by height in metres squared. Early-life BMI was measured at 18 years in the Nurses’ Health Study and at 21 years in the Health Professionals Follow-up

Study. Each cohort administered food-frequency questionnaires (~130 food items) to obtain information on usual dietary intake over the previous year at baseline and repeated almost every 4

years thereafter, which allowed us to calculate intakes of nutrients and foods such as alcohol, calories, calcium, dietary fibre, sugar, carbohydrates, folate, vitamin D, processed meat, and

red meat.42,43,44,45,46 IDENTIFICATION OF COLORECTAL CANCER CASES In both cohorts, we identified cases of colorectal cancer through biennial questionnaires.47 All possible cancer cases were

confirmed through review of medical and pathological records. The incident colorectal cancer cases were defined as a primary tumour with International Classification of Diseases-9 codes of

153 and 154. A study physician who was blinded to exposure data abstracted information on tumour anatomic location, stage, and histology. We searched state vital statistics records and the

National Death Index to identify additional unreported cancer deaths. In this analysis, we considered both overall colorectal cancer and anatomic subsites, including colon cancer, proximal

colon cancer (caecum, ascending colon, and transverse colon), distal colon cancer (descending colon and sigmoid colon), and rectal cancer (including recto-sigmoid). STATISTICAL ANALYSES

Person-time for participants was calculated from the return of the baseline questionnaires until the date of colorectal cancer diagnosis, death, loss to follow-up, or the end of the

follow-up (June 2012 for the Nurses’ Health Study and January 2012 for the Health Professionals Follow-up Study), whichever came first. Consistent with our previous report,7 we evaluated the

association with status (no versus yes) and duration of type 2 diabetes (0.1–5, 5.1–10, 10.1–15, and >15 years) within each cohort. We used Cox regression models to calculate the

multivariable hazard ratios (HRs) and 95% confidence intervals (95% CIs). Age in months and calendar year at the start of follow-up of each 2-year questionnaire cycle were used as

stratification variables in the model. In the multivariable analyses, we adjusted for race (Whites or non-Whites); family history of diabetes (yes or no); regular aspirin use (yes or no);

BMI (<25, 25–<27.5, 27.5–<30, ≥30 kg/m2); history of colorectal cancer in a parent or sibling (yes or no); history of endoscopy/sigmoidoscopy (yes or no); smoking habits (0, 1–10,

or >10 pack-years); alcohol consumption (<5, 5–<15, ≥15 g/day); physical activity (<3, 3–<27, ≥27 METS-hours/week); total calories (tertiles); energy-adjusted intake of total

folate; total calcium; total vitamin D; processed meat; and beef, pork, or lamb as a main dish (all in tertiles). For women, we additionally adjusted for postmenopausal hormone use

(premenopausal, never, past, or current user). Confounders were updated over the follow-up periods to reduce random within-person measurement error. Test of statistical heterogeneity in the

association of type 2 diabetes and colorectal cancer risk by gender was assessed by the Q statistics.48 For the two cohorts, there were about 0.1–3% missing data in processed meat, beef,

pork, or lamb as the main dish or for family history of colorectal cancer. Given the generally low proportion of missing data in these covariates, we have included the individuals with

missing in family history of colorectal cancer in the no family history group and missing in intake of processed meat or beef, pork, or lamb as the main dish in the tertile 1 group. Previous

studies have suggested that smoking20 may modify the association between diabetes and colorectal cancer; and BMI, physical activity, and moderate alcohol consumption are associated with

insulin resistance.49,50,51 Therefore, we considered these potential variables that might modify the diabetes and colorectal cancer risk associations. We conducted subgroup analyses by

smoking status (never smoker versus ever smoker), BMI (≥25 versus <25 kg/m2), early life BMI (≥23 versus <23 kg/m2), physical activity (<9 versus ≥9 METS-hours/week), alcohol

drinking (non-drinkers versus drinkers), and other selected risk factors including age (≥65 versus <65 years) and family history of diabetes (yes versus no). We used Wald test to examine

whether the cross-product terms between these variables and diabetes status were statistically significant. We conducted several secondary analyses. First, we evaluated whether the

associations between diabetes (status and duration) and colorectal cancer risk differed by anatomic subsites (colon cancer, proximal colon cancer, distal colon cancer, and rectal cancer).28

Second, we restricted analyses to untreated diabetes by excluding patients with type 2 diabetes who have used hypoglycaemic medication (insulin or oral hypoglycaemic agent). A total of 195

cases (146 for women and 49 for men) were excluded from our analysis to investigate whether diabetes treatments affect the association between type 2 diabetes and colorectal cancer risk.

Last, we excluded colorectal cancer cases diagnosed within 1 year of diabetes diagnosis to minimise the potential for reverse causality and detection bias. All statistical analyses were

conducted using the SAS software (Version 9.3; SAS Institute, Cary, NC, USA). All statistical tests were two sided, and the significance level was set at _P_ < 0.05. RESULTS During

3,547,837 person-years of follow-up, we documented a total of 3000 incident cases of colorectal cancer (1790 in women and 1210 in men). In both cohorts, participants with type 2 diabetes

were older and more likely to smoke and have a family history of diabetes (Table 1). Moreover, participants with type 2 diabetes were more likely to have higher BMI and use aspirin and were

less likely to be physically active, drink alcohol, and consume sugar. Patients with longer duration of type 2 diabetes generally tended to be more physically active and consume less sugar

and carbohydrates but were more likely to consume processed meats (especially in men). Among men, type 2 diabetes was associated with increased risk of incident colorectal cancer

(multivariable HR: 1.42; 95% CI: 1.12–1.81) (Table 2). The positive association for men persisted in sensitivity analyses excluding colorectal cancer cases diagnosed within 1 year of type 2

diabetes diagnosis (multivariable HR: 1.40; 95% CI: 1.10–1.78). Additionally, we observed similar positive associations for each tumour anatomic subsite (Supplementary Table 1) and when we

restricted cases to only those with untreated diabetes (Supplementary Table 2_)_. Among women, type 2 diabetes showed only a modest, borderline significant association with colorectal cancer

risk (HR: 1.17; 95% CI: 0.98–1.39) (Table 2). The heterogeneity test did not achieve statistical significance (_P_ = 0.20 for men versus women). Colorectal cancer risk did not vary with

type 2 diabetes duration in either men or women. In stratified analyses (Table 3), the association between type 2 diabetes and colorectal cancer risk appeared slightly stronger among ever

smokers (_P-interaction_ = 0.04 for women) and non-drinkers (_P-interaction_ = 0.05 for men). Additionally, the association was also slightly stronger for those with higher BMI or early life

BMI and individuals with a family history of diabetes, but none of the _P_-values were statistically significant. DISCUSSION In these two large prospective cohort studies, with >26 years

of follow-up, we found that type 2 diabetes was associated with a moderately higher risk of incident colorectal cancer in men; a weaker, nonsignificant positive association was observed in

women. The positive association for men remained in sensitivity analyses that accounted for potential reverse causality by excluding colorectal cancer cases diagnosed within 1 year of

diagnosis of type 2 diabetes and diabetes treatments and did not vary by diabetes duration. In our previous study with follow-up through 1994,7 we reported a significant association between

type 2 diabetes and colorectal cancer risk among women in the Nurses’ Health Study (HR: 1.43; 95% CI: 1.10–1.87). Positive associations of similar magnitude were reported for the women in

the Cancer Prevention Study II17 and the Iowa Women’s Health Study16 with follow-up through 1998 and 1999, respectively. In 2005, a meta-analysis of 15 studies (6 case–control and 9 cohort

studies, including our prior Nurses’ Health Study report) reported positive associations for diabetes and colorectal cancer risk of similar magnitude for men (HR: 1.29; 95% CI: 1.15–1.44)

and women (HR: 1.33; 95% CI: 1.23–1.44).9 However, most subsequent studies have reported a weaker positive14 or a null association3,18,20,21,22 between type 2 diabetes and colorectal cancer

risk among women. This was consistent with our observation of a slightly weaker association in women but a moderately higher-risk association in men. The possible differential association

between women and men observed might be due to potential sex differences in the use of metformin and degree of glucose control.3 Compared with men, metformin has been more commonly used

among women since the late 1990s.52 However, the potential effect of metformin use and colorectal cancer risk is not completely understood and more better designed studies are warranted to

quantify the magnitude of the association between metformin use and colorectal cancer risk. Additionally, women generally tend to have better glucose control than men, even among those with

type 2 diabetes.3 In fact, among individuals with type 2 diabetes, this difference is increasing. The National Health and Nutrition Examination Survey data showed that women with type 2

diabetes, but not men, have statistically significantly improved haemoglobin A1c (an indicator of glucose control) during the period from 1999 to 2004 in the US.53 Furthermore, differences

in sex hormones may contribute to a more insulin-sensitive environment in women than in men. It may protect women from adverse outcomes related to hyperinsulinaemia.54,55 Observational

studies30,31,32,33,34,56 suggested an inverse association of endogenous oestrogens with the risk of colorectal cancer among women. Particularly, compared with women, men may have a higher

insulin resistance partly due to the lack the protective effect of oestrogen.54,55 Despite relatively comprehensive research on type 2 diabetes in relation to risk of colorectal cancer,29

current findings are inconsistent with regard to the potential gender difference. We observed a slightly stronger association in men than in women in this study but there was no

statistically significant heterogeneity by gender. Nonetheless, the association between type 2 diabetes and colorectal cancer is strongly influenced by shared risk factors such as genetic

variants, obesity, smoking, alcohol, and lack of physical activity.57,58 These potential factors might modify the diabetes and colorectal cancer risk differently in women and men, which

requires further investigation. We found that the type 2 diabetes–colorectal cancer association did not appear to be associated with diabetes duration. Because beta cells in the pancreas

produce lower insulin levels as diabetes progresses into later stage, if hyperinsulinaemia plays a key role in this association, stronger positive associations would be expected in the early

stage of diabetes. Thus our results did not support a strong role of hyperinsulinaemia in diabetes–colorectal cancer association. We found slightly stronger associations between type 2

diabetes and colorectal cancer among ever smokers. This observation was consistent with a population-based, retrospective cohort study, which reported a stronger positive association among

smokers.20 We also found a stronger association among non-drinkers of alcohol, indicating a potential interactive effect of alcohol consumption on type 2 diabetes. A similar, though not

statistically significant, pattern was observed in women. Similar to that seen in cardiovascular disease,59 light-to-moderate intake of alcohol was associated with the reduced risk of

colorectal cancer in some studies.60,61,62 Light-to-moderate alcohol consumption may increase insulin sensitivity and thus reduce insulin production.49,50 This was consistent with the

observation that moderate alcohol consumption was associated with lower levels of plasma C-peptide and lower risk of colorectal cancer.63 Thus the potential interaction between insulin and

alcohol may protect patients with type 2 diabetes from serious outcomes of hyperinsulinaemia. However, the underlying mechanisms warrant further investigation. Our present study has several

strengths, including the prospective cohort design, high follow-up rates, validated colorectal cancer outcomes, and the use of repeated measures of physician-confirmed diabetes and lifestyle

data. Our study also has several limitations. First, we have limited data on diabetes treatment. The observed association could be influenced by diabetes treatments because medications used

to treat diabetes such as insulin injection64 or metformin use65 may affect the incidence of colorectal cancer. Moreover, we have limited data on glucose control because hyperglycaemia will

also affect the cancer risk. However, the results were similar when we restricted the analysis among untreated diabetes (without any use of insulin or other hypoglycaemic agents). Second,

our results might be influenced by detection bias, because newly diagnosed diabetes is more likely to be diagnosed with cancer due to increased detection around the time of the diagnosis of

diabetes.66 However, we observed similar positive association when we excluded cases diagnosed within 1 year since type 2 diabetes. In summary, our study suggests that type 2 diabetes was

associated with a moderately higher risk of incident colorectal cancer in men; a weaker, nonsignificant association was observed in women. More studies are warranted to further investigate

the underlying mechanisms. Our finding further underscores the importance of enhancing the effort to reduce the emerging epidemics of type 2 diabetes for colorectal cancer prevention and

control. REFERENCES * Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2012. _CA Cancer J. Clin._ 62, 10–29 (2012). Article  Google Scholar  * Torre, L. A. et al. Global cancer

statistics, 2012. _CA Cancer J. Clin._ 65, 87–108 (2015). Article  Google Scholar  * Campbell, P. T. et al. Prospective study reveals associations between colorectal cancer and type 2

diabetes mellitus or insulin use in men. _Gastroenterology_ 139, 1138–1146 (2010). Article  Google Scholar  * Cavicchia, P. P. et al. Racial disparities in colorectal cancer incidence by

type 2 diabetes mellitus status. _Cancer Causes Control_ 24, 277–285 (2013). Article  Google Scholar  * Flood, A., Strayer, L., Schairer, C. & Schatzkin, A. Diabetes and risk of incident

colorectal cancer in a prospective cohort of women. _Cancer Causes Control_ 21, 1277–1284 (2010). Article  Google Scholar  * He, J. et al. The association of diabetes with colorectal cancer

risk: the multiethnic cohort. _Br. J. Cancer_ 103, 120–126 (2010). Article  CAS  Google Scholar  * Hu, F. B. et al. Prospective study of adult onset diabetes mellitus (type 2) and risk of

colorectal cancer in women. _J. Natl. Cancer Inst._ 91, 542–547 (1999). Article  CAS  Google Scholar  * Larsson, S. C., Giovannucci, E. & Wolk, A. Diabetes and colorectal cancer

incidence in the cohort of Swedish men. _Diabetes Care_ 28, 1805–1807 (2005). Article  Google Scholar  * Larsson, S. C., Orsini, N. & Wolk, A. Diabetes mellitus and risk of colorectal

cancer: a meta-analysis. _J. Natl. Cancer Inst._ 97, 1679–1687 (2005). Article  Google Scholar  * Nilsen, T. I. & Vatten, L. J. Prospective study of colorectal cancer risk and physical

activity, diabetes, blood glucose and BMI: exploring the hyperinsulinaemia hypothesis. _Br. J. Cancer_ 84, 417–422 (2001). Article  CAS  Google Scholar  * Peeters, P. J., Bazelier, M. T.,

Leufkens, H. G., de Vries, F. & De Bruin, M. L. The risk of colorectal cancer in patients with type 2 diabetes: associations with treatment stage and obesity. _Diabetes Care_ 38, 495–502

(2015). Article  Google Scholar  * Sun, L. & Yu, S. Diabetes mellitus is an independent risk factor for colorectal cancer. _Dig. Dis. Sci._ 57, 1586–1597 (2012). Article  Google Scholar

  * Yang, Y. X., Hennessy, S. & Lewis, J. D. Type 2 diabetes mellitus and the risk of colorectal cancer. _Clin. Gastroenterol. Hepatol._ 3, 587–594 (2005). Article  Google Scholar  *

Seow, A., Yuan, J. M., Koh, W. P., Lee, H. P. & Yu, M. C. Diabetes mellitus and risk of colorectal cancer in the Singapore Chinese Health Study. _J. Natl. Cancer Inst._ 98, 135–138

(2006). Article  Google Scholar  * Lee, M. S. et al. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative

population prospective cohort study of 800,000 individuals. _BMC Cancer_ 11, 20 (2011). Article  CAS  Google Scholar  * Limburg, P. J. et al. Diabetes mellitus and subsite-specific

colorectal cancer risks in the Iowa Women’s Health Study. _Cancer Epidemiol. Biomark. Prev._ 14, 133–137 (2005). Google Scholar  * Coughlin, S. S., Calle, E. E., Teras, L. R., Petrelli, J.

& Thun, M. J. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. _Am. J. Epidemiol._ 159, 1160–1167 (2004). Article  Google Scholar  * Inoue, M. et al.

Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. _Arch. Intern. Med._ 166, 1871–1877 (2006). Article  Google Scholar  * de Kort,

S. et al. Diabetes mellitus type 2 and subsite-specific colorectal cancer risk in men and women: results from the Netherlands Cohort Study on diet and cancer. _Eur. J. Gastroenterol.

Hepatol._ 28, 896–903 (2016). Article  Google Scholar  * Limburg, P. J. et al. Clinically confirmed type 2 diabetes mellitus and colorectal cancer risk: a population-based, retrospective

cohort study. _Am. J. Gastroenterol._ 101, 1872–1879 (2006). Article  Google Scholar  * Kuriki, K., Hirose, K. & Tajima, K. Diabetes and cancer risk for all and specific sites among

Japanese men and women. _Eur. J. Cancer Prev._ 16, 83–89 (2007). Article  Google Scholar  * Ren, X. et al. Type 2 diabetes mellitus associated with increased risk for colorectal cancer:

evidence from an international ecological study and population-based risk analysis in China. _Public Health_ 123, 540–544 (2009). Article  CAS  Google Scholar  * Tabak, A. G. et al.

Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. _Lancet_ 373, 2215–2221 (2009). Article 

CAS  Google Scholar  * Giovannucci, E. Insulin and colon cancer. _Cancer Causes Control_ 6, 164–179 (1995). Article  CAS  Google Scholar  * Vigneri, P., Frasca, F., Sciacca, L., Pandini, G.

& Vigneri, R. Diabetes and cancer. _Endocr. Relat. Cancer_ 16, 1103–1123 (2009). Article  CAS  Google Scholar  * Luo, W., Cao, Y., Liao, C. & Gao, F. Diabetes mellitus and the

incidence and mortality of colorectal cancer: a meta-analysis of 24 cohort studies. _Colorectal Dis._ 14, 1307–1312 (2012). Article  CAS  Google Scholar  * Guraya, S. Y. Association of type

2 diabetes mellitus and the risk of colorectal cancer: a meta-analysis and systematic review. _World J. Gastroenterol._ 21, 6026–6031 (2015). Article  CAS  Google Scholar  * Guraya, S. Y.

& Eltinay, O. E. Higher prevalence in young population and rightward shift of colorectal carcinoma. _Saudi. Med. J._ 27, 1391–1393 (2006). PubMed  Google Scholar  * Tsilidis, K. K.,

Kasimis, J. C., Lopez, D. S., Ntzani, E. E. & Ioannidis, J. P. Type 2 diabetes and cancer: umbrella review of meta-analyses of observational studies. _BMJ_ 350, g7607 (2015). Article 

Google Scholar  * Clendenen, T. V. et al. Postmenopausal levels of endogenous sex hormones and risk of colorectal cancer. _Cancer Epidemiol. Biomark. Prev._ 18, 275–281 (2009). Article  CAS

  Google Scholar  * Falk, R. T. et al. Estrogen metabolites are not associated with colorectal cancer risk in postmenopausal women. _Cancer Epidemiol. Biomark. Prev._ 24, 1419–1422 (2015).

Article  CAS  Google Scholar  * Gunter, M. J. et al. Insulin, insulin-like growth factor-I, endogenous estradiol, and risk of colorectal cancer in postmenopausal women. _Cancer Res._ 68,

329–337 (2008). Article  CAS  Google Scholar  * Lin, J. H. et al. Association between sex hormones and colorectal cancer risk in men and women. _Clin. Gastroenterol. Hepatol._ 11, 419–424

e411 (2013). Article  CAS  Google Scholar  * Murphy, N. et al. A prospective evaluation of endogenous sex hormone levels and colorectal cancer risk in postmenopausal women. _J. Natl. Cancer.

Inst_. 107; https://doi.org/10.1093/jnci/djv210 (2015). Article  Google Scholar  * Shin, C. M. et al. Association among obesity, metabolic health, and the risk for colorectal cancer in the

general population in Korea using the National Health Insurance Service-National Sample Cohort. _Dis. Colon Rectum_ 60, 1192–1200 (2017). Article  Google Scholar  * Colditz, G. A. et al.

Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. _Am. J. Epidemiol._ 123, 894–900 (1986). Article  CAS  Google Scholar  *

Simon, T. G. et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: results from two prospective cohort studies. _Hepatology_ 67, 1797–1806 (2018). Article  CAS 

Google Scholar  * Cornelis, M. C. et al. Joint effects of common genetic variants on the risk for type 2 diabetes in U.S. men and women of European ancestry. _Ann. Intern. Med._ 150, 541–550

(2009). Article  Google Scholar  * Manson, J. E. et al. Physical activity and incidence of non-insulin-dependent diabetes mellitus in women. _Lancet_ 338, 774–778 (1991). Article  CAS 

Google Scholar  * Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. National Diabetes Data Group. _Diabetes_ 28, 1039–1057 (1979). * Hu, F. B. et

al. Physical activity and television watching in relation to risk for type 2 diabetes mellitus in men. _Arch. Intern. Med._ 161, 1542–1548 (2001). Article  CAS  Google Scholar  * Willett,

W. C. et al. Reproducibility and validity of a semiquantitative food frequency questionnaire. _Am. J. Epidemiol._ 122, 51–65 (1985). Article  CAS  Google Scholar  * Wu, K., Willett, W. C.,

Fuchs, C. S., Colditz, G. A. & Giovannucci, E. L. Calcium intake and risk of colon cancer in women and men. _J. Natl. Cancer Inst._ 94, 437–446 (2002). Article  Google Scholar  * Rimm,

E. B. et al. Reproducibility and validity of an expanded self-administered semiquantitative food frequency questionnaire among male health professionals. _Am. J. Epidemiol._ 135, 1114–1126

(1992). discussion 1127–1136. Article  CAS  Google Scholar  * Salvini, S. et al. Food-based validation of a dietary questionnaire: the effects of week-to-week variation in food consumption.

_Int. J. Epidemiol._ 18, 858–867 (1989). Article  CAS  Google Scholar  * Feskanich, D. et al. Reproducibility and validity of food intake measurements from a semiquantitative food frequency

questionnaire. _J. Am. Diet. Assoc._ 93, 790–796 (1993). Article  CAS  Google Scholar  * Willett, W. C. et al. Dietary fat and fiber in relation to risk of breast cancer. An 8-year

follow-up. _JAMA_ 268, 2037–2044 (1992). Article  CAS  Google Scholar  * Cochran, W. G. The combination of estimates from different experiments. _Biometrics_ 10, 101–129 (1954). Article 

Google Scholar  * Facchini, F., Chen, Y. D. & Reaven, G. M. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. _Diabetes Care_ 17, 115–119 (1994). Article

  CAS  Google Scholar  * Kiechl, S. et al. Insulin sensitivity and regular alcohol consumption: large, prospective, cross sectional population study (Bruneck study). _BMJ_ 313, 1040–1044

(1996). Article  CAS  Google Scholar  * Hamasaki, H. et al. Daily physical activity assessed by a triaxial accelerometer is beneficially associated with waist circumference, serum

triglycerides, and insulin resistance in Japanese patients with prediabetes or untreated early type 2 diabetes. _J Diabetes Res._ 2015, 526201 (2015). Article  Google Scholar  * Cohen, F.

J., Neslusan, C. A., Conklin, J. E. & Song, X. Recent antihyperglycemic prescribing trends for US privately insured patients with type 2 diabetes. _Diabetes Care_ 26, 1847–1851 (2003).

Article  Google Scholar  * Hoerger, T. J., Segel, J. E., Gregg, E. W. & Saaddine, J. B. Is glycemic control improving in U.S. adults? _Diabetes Care_ 31, 81–86 (2008). Article  Google

Scholar  * Rondini, E. A., Harvey, A. E., Steibel, J. P., Hursting, S. D. & Fenton, J. I. Energy balance modulates colon tumor growth: interactive roles of insulin and estrogen. _Mol.

Carcinog._ 50, 370–382 (2011). Article  CAS  Google Scholar  * Geer, E. B. & Shen, W. Gender differences in insulin resistance, body composition, and energy balance. _Gend. Med._ 6(Suppl

1), 60–75 (2009). Article  Google Scholar  * Chlebowski, R. T. et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. _N. Engl. J. Med._ 350, 991–1004 (2004). Article

  CAS  Google Scholar  * Sainz, J. et al. Effect of type 2 diabetes predisposing genetic variants on colorectal cancer risk. _J. Clin. Endocrinol. Metab._ 97, E845–E851 (2012). Article  CAS

  Google Scholar  * Kramer, H. U., Schottker, B., Raum, E. & Brenner, H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. _Eur. J. Cancer_ 48,

1269–1282 (2012). Article  Google Scholar  * Bell, R. A. et al. Associations between alcohol consumption and insulin sensitivity and cardiovascular disease risk factors: the Insulin

Resistance and Atherosclerosis Study. _Diabetes Care_ 23, 1630–1636 (2000). Article  CAS  Google Scholar  * Klarich, D. S., Brasser, S. M. & Hong, M. Y. Moderate alcohol consumption and

colorectal cancer risk. _Alcohol. Clin. Exp. Res._ 39, 1280–1291 (2015). Article  CAS  Google Scholar  * Kontou, N. et al. Alcohol consumption and colorectal cancer in a Mediterranean

population: a case-control study. _Dis. Colon Rectum_ 55, 703–710 (2012). Article  Google Scholar  * Park, J. Y. et al. Baseline alcohol consumption, type of alcoholic beverage and risk of

colorectal cancer in the European Prospective Investigation into Cancer and Nutrition-Norfolk study. _Cancer Epidemiol._ 33, 347–354 (2009). Article  CAS  Google Scholar  * Ma, J. et al. A

prospective study of plasma C-peptide and colorectal cancer risk in men. _J. Natl. Cancer Inst._ 96, 546–553 (2004). Article  CAS  Google Scholar  * Yin, S., Bai, H. & Jing, D. Insulin

therapy and colorectal cancer risk among type 2 diabetes mellitus patients: a systemic review and meta-analysis. _Diagn. Pathol._ 9, 91 (2014). Article  Google Scholar  * Liu, F. et al.

Metformin therapy and risk of colorectal adenomas and colorectal cancer in type 2 diabetes mellitus patients: a systematic review and meta-analysis. _Oncotarget_ 8, 16017–16026 (2017).

PubMed  Google Scholar  * Johnson, J. A., Bowker, S. L., Richardson, K. & Marra, C. A. Time-varying incidence of cancer after the onset of type 2 diabetes: evidence of potential

detection bias. _Diabetologia_ 54, 2263–2271 (2011). Article  CAS  Google Scholar  Download references ACKNOWLEDGEMENTS We would like to thank the participants and staff of the Nurses’

Health Study and the Health Professionals Follow-up Study for their valuable contributions as well as the following state cancer registries for their help: A.L., A.Z., A.R., C.A., C.O.,

C.T., D.E., F.L., G.A., I.D., I.L., I.N., I.A., K.Y., L.A., M.E., M.D., M.A., M.I., N.E., N.H., N.J., N.Y., N.C., N.D., O.H., O.K., O.R., P.A., R.I., S.C., T.N., T.X., V.A., W.A., W.Y.

AUTHOR INFORMATION AUTHORS AND AFFILIATIONS * School of Public Health, China Medical University, Shenyang, Liaoning, P.R. China Yanan Ma & Deliang Wen * Channing Division of Network

Medicine, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA Yanan Ma, Wanshui Yang, Frank B. Hu, Andrew T. Chan, Edward L. Giovannucci & 

Xuehong Zhang * Department of Nutrition, School of Public Health, Anhui Medical University, Hefei, Anhui, P.R. China Wanshui Yang * Department of Nutrition, Harvard T.H. Chan School of

Public Health, Boston, MA, USA Mingyang Song, Stephanie A. Smith-Warner, Yanping Li, Yang Hu, Frank B. Hu & Edward L. Giovannucci * Clinical and Translational Epidemiology Unit,

Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA Mingyang Song & Andrew T. Chan * Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, USA

Mingyang Song & Andrew T. Chan * Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA Stephanie A. Smith-Warner & Yang Hu * 2011 Collaborative

Innovation Center of Tianjin for Medical Epigenetics, Key Laboratory of Hormone and Development (Ministry of Health), Metabolic Disease Hospital and Tianjin Institute of Endocrinology,

Tianjin Medical University, 300070, Tianjin, P.R. China Juhong Yang * Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA Wenjie Ma, Shuji Ogino & 

Edward L. Giovannucci * Department of Oncologic Pathology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA Shuji Ogino * Broad Institute of Massachusetts Institute

of Technology and Harvard, Cambridge, MA, USA Shuji Ogino & Andrew T. Chan * Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women’s Hospital and

Harvard Medical School, Boston, MA, USA Shuji Ogino * Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA Andrew T. Chan Authors *

Yanan Ma View author publications You can also search for this author inPubMed Google Scholar * Wanshui Yang View author publications You can also search for this author inPubMed Google

Scholar * Mingyang Song View author publications You can also search for this author inPubMed Google Scholar * Stephanie A. Smith-Warner View author publications You can also search for this

author inPubMed Google Scholar * Juhong Yang View author publications You can also search for this author inPubMed Google Scholar * Yanping Li View author publications You can also search

for this author inPubMed Google Scholar * Wenjie Ma View author publications You can also search for this author inPubMed Google Scholar * Yang Hu View author publications You can also

search for this author inPubMed Google Scholar * Shuji Ogino View author publications You can also search for this author inPubMed Google Scholar * Frank B. Hu View author publications You

can also search for this author inPubMed Google Scholar * Deliang Wen View author publications You can also search for this author inPubMed Google Scholar * Andrew T. Chan View author

publications You can also search for this author inPubMed Google Scholar * Edward L. Giovannucci View author publications You can also search for this author inPubMed Google Scholar *

Xuehong Zhang View author publications You can also search for this author inPubMed Google Scholar CONTRIBUTIONS Y.M. wrote the paper. Y.M. and W.Y. did the statistical analysis, supervised

by X.Z. All authors contributed to the data interpretation, revised each draft for important intellectual content, and read and approved the final manuscript. CORRESPONDING AUTHOR

Correspondence to Xuehong Zhang. ETHICS DECLARATIONS COMPETING INTERESTS The authors declare no competing interests. AVAILABILITY OF DATA AND MATERIALS The data sets generated during and/or

analysed during the current study are available for non-commercial use from the corresponding author on reasonable request. ETHICAL APPROVAL/CONSENT TO PARTICIPATE The study protocol was

approved by the institutional review board of the Brigham and Women’s Hospital and the Human Subjects Committee Review Board of the Harvard T. H. Chan School of Public Health. FUNDING No

external funding was used for conducting this study. NOTE This work is published under the standard license to publish agreement. After 12 months the work will become freely available and

the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0). ELECTRONIC SUPPLEMENTARY MATERIAL SUPPLEMENTARY TABLE 1, SUPPLEMENTARY TABLE 2 RIGHTS AND

PERMISSIONS This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits

unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,

and indicate if changes were made. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Ma, Y., Yang, W., Song, M. _et al._ Type 2 diabetes and risk of colorectal cancer in two

large U.S. prospective cohorts. _Br J Cancer_ 119, 1436–1442 (2018). https://doi.org/10.1038/s41416-018-0314-4 Download citation * Received: 05 May 2018 * Revised: 27 September 2018 *

Accepted: 03 October 2018 * Published: 07 November 2018 * Issue Date: 27 November 2018 * DOI: https://doi.org/10.1038/s41416-018-0314-4 SHARE THIS ARTICLE Anyone you share the following link

with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative